DRG Instruments Unveils Innovative TBI Testing Panel at MEDLAB in Dubai
DRG Instruments GmbH, a prominent developer and manufacturer of immunoassays for over 50 years, is setting a new benchmark in the field of neuroscience with its innovative testing solutions for traumatic brain injuries (TBI). Recently, at the MEDLAB Middle East event in Dubai, which runs from February 3 to 6, the company showcased its automated CLIA tests specifically designed for assessing suspected TBIs. These tests, known as GFAP and UCH-L1 combo tests, allow for the timely measurement of GFAP and UCH-L1 blood levels within just 30 minutes, provided that serum samples are collected within a 12-hour window following a suspected incident.
This swift diagnostic capability is critical for ensuring rapid and effective treatment for patients who may have experienced traumatic brain injuries. Furthermore, by facilitating a faster evaluation of head injuries, DRG's tests significantly reduce the reliance on radiation-based imaging methodologies, thus improving patient assessment and care. Joerg Schloesser, Managing Director and VP of Commercial at DRG, expressed his excitement about bringing these innovative solutions to the global market. He stated, "By leveraging automated tests and quick turnaround times, we empower healthcare professionals to make faster and more informed decisions. Our goal is to enhance patient care for individuals suffering from traumatic brain injuries worldwide."
The TBI tests developed by DRG have received CE marking and meet the rigorous standards outlined by the Clinical and Laboratory Standards Institute (CLSI). These tests are intended for clinical laboratory environments and are suitable for patients aged 18 and over.
Healthcare professionals and stakeholders interested in learning more about the availability of these tests can reach out to DRG representatives or visit their official website for additional information. For those attending the MEDLAB event, DRG's product development team will be present at Hall 1, Stand G50, ready to answer any questions regarding the TBI tests.
The establishment of DRG's new division, DRG Neuroscience, signifies the company's commitment to advancing the medical community's capabilities in diagnosing and treating traumatic brain injuries. Founded in 1973 and headquartered in Marburg, DRG Instruments has a rich history of innovation, having pioneered numerous immunoassays for both routine and research applications. With distribution partners in over 120 countries, and as an ISO 13485-certified company, DRG adheres to FDA standards and is dedicated to continuing its legacy of providing high-quality diagnostic solutions.
In conclusion, the introduction of these automated TBI tests marks a substantial improvement in the field of emergency medicine, offering healthcare providers an essential tool in their diagnostic arsenal, ultimately aiming to improve outcomes for patients with traumatic brain injuries.
This swift diagnostic capability is critical for ensuring rapid and effective treatment for patients who may have experienced traumatic brain injuries. Furthermore, by facilitating a faster evaluation of head injuries, DRG's tests significantly reduce the reliance on radiation-based imaging methodologies, thus improving patient assessment and care. Joerg Schloesser, Managing Director and VP of Commercial at DRG, expressed his excitement about bringing these innovative solutions to the global market. He stated, "By leveraging automated tests and quick turnaround times, we empower healthcare professionals to make faster and more informed decisions. Our goal is to enhance patient care for individuals suffering from traumatic brain injuries worldwide."
The TBI tests developed by DRG have received CE marking and meet the rigorous standards outlined by the Clinical and Laboratory Standards Institute (CLSI). These tests are intended for clinical laboratory environments and are suitable for patients aged 18 and over.
Healthcare professionals and stakeholders interested in learning more about the availability of these tests can reach out to DRG representatives or visit their official website for additional information. For those attending the MEDLAB event, DRG's product development team will be present at Hall 1, Stand G50, ready to answer any questions regarding the TBI tests.
The establishment of DRG's new division, DRG Neuroscience, signifies the company's commitment to advancing the medical community's capabilities in diagnosing and treating traumatic brain injuries. Founded in 1973 and headquartered in Marburg, DRG Instruments has a rich history of innovation, having pioneered numerous immunoassays for both routine and research applications. With distribution partners in over 120 countries, and as an ISO 13485-certified company, DRG adheres to FDA standards and is dedicated to continuing its legacy of providing high-quality diagnostic solutions.
In conclusion, the introduction of these automated TBI tests marks a substantial improvement in the field of emergency medicine, offering healthcare providers an essential tool in their diagnostic arsenal, ultimately aiming to improve outcomes for patients with traumatic brain injuries.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.